Perfusion Medical, Inc.
CT
- UEI
- XEDJGXP1K889
- CAGE
- 8MYE9
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- Connecticut, USA
- Website
- perfusionmedical.com
- Founded
- 2020
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $1,499,773 |
| FY2025 | $0 |
| FY2024 | $3,784,184 |
| FY2023 | $3,136,669 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Defense Health Agency | $1,499,773 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Memsel Inc. | Fort Worth, TX | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Biocryst Pharmaceuticals Inc. | Durham, NC | 325412 Pharmaceutical Preparation Manufacturing |
| Inaedis, Inc. | Princeton, NJ | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Isola Therapeutics Inc. | Minneapolis, MN | 339112 Surgical and Medical Instrument Manufacturing |
| Kalocyte Inc. | Baltimore, MD | 541713 Research and Development in Nanotechnology |
About the company
Perfusion Medical, Inc., a small biotechnology company based in Connecticut, develops innovative intravenous therapeutics for acute medical emergencies and serves the federal government exclusively as a prime contractor under total small business set-asides, with no subcontract footprint across its nine recent federal awards.
Perfusion Medical's core capability is the research, development, and clinical advancement of PEG-20K/8K (polyethylene glycol-based formulation), a novel patented intravenous solution designed to treat septic shock, hemorrhagic shock, and acute kidney injury in pre-hospital and field settings. The company commercializes a technology originally developed at Virginia Commonwealth University and collaborates with Mayo Clinic and Virginia Commonwealth University on clinical validation and dosing optimization. Federal work centers on IND-enabling studies, human clinical trials for safety assessment, optimal dosing and formulation refinement, and mechanistic research into tissue perfusion preservation during sepsis. Representative work includes a $2.99 million Defense Health Agency SBIR Phase II contract (awarded September 2023, completing July 2026) for IND-enabling studies of PM-208; two Air Force Research Laboratory STTR Phase II purchase orders totaling $3.6 million (one awarded February 2024, completing April 2026; a second awarded June 2024, completing January 2027) for human clinical trials and optimal dosing research; a $1.5 million Defense Health Agency definitive contract (awarded April 2026, completing August 2027) for IND-enabling studies; and a $275,000 National Institute of General Medical Sciences R41 grant (awarded September 2021, completed December 2022) for polymer-based tissue perfusion research. Herndon, Virginia, is the primary place of performance.
Customer concentration splits between two federal agencies. The Defense Health Agency accounts for two awards valued at $4.5 million in combined potential value, anchoring the dollar base. The Air Force Research Laboratory dominates award volume with six contracts valued at $3.9 million combined potential value, spanning STTR Phase I and Phase II work and SBIR Phase I research. The National Institute of General Medical Sciences contributed one grant award. All work is designated total small business set-aside; Perfusion Medical competes exclusively under small business protections across its federal footprint.
Activity has been episodic. The source records one award in 2021, a gap in 2022, four awards in 2023, three in 2024, and one in 2026. Two awards totaling $3.3 million in combined potential value face completion within the next twenty-four months and will enter recompete. The combined potential value of $8.4 million across nine awards reflects the early-stage biotechnology and clinical development profile typical of SBIR and STTR portfolios; obligated dollars ($9.2 million) have exceeded the stated potential-value ceiling, indicating cost growth or scope adjustments during performance.
Quick answers
Is Perfusion Medical, Inc. registered in SAM.gov?
Yes. Perfusion Medical, Inc.'s SAM.gov registration is active through June 5, 2027.
What is Perfusion Medical, Inc.'s CAGE code?
Perfusion Medical, Inc.'s CAGE code is 8MYE9, and its Unique Entity ID (UEI) is XEDJGXP1K889.
How much has Perfusion Medical, Inc. received in federal contracts?
Federal contracts obligated $8,420,626 to Perfusion Medical, Inc. in fiscal years 2023 through 2027.
What is Perfusion Medical, Inc.'s most recent federal award?
Perfusion Medical, Inc.'s most recent federal contract award is IND-enabling studies of PM-208: a novel pre-hospital anti-shock therapeutic (HT942726CE025), from Defense Health Agency, on April 2, 2026.
On GovTribe
See Perfusion Medical, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors